Coherus Oncology, Inc.CHRSNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 81% recommend buying.

Consensus Rating

Buy

16 analysts·Moderate coverage

81%

Rating Distribution

Strong Buy

00%

Buy

1381%

Hold

319%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 179% higher.

Bear Case

$1.05

-51%

Consensus

$6.02

+179%

Bull Case

$11.00

+409%

Price Range16 analysts

Low

Consensus

High

$1.05

$11.00

Current Target

Current Price

$2.16

Upside to Target

$3.86

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-1.12(2 analysts)

P/E2x

Current: 1.6x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+25.24%

EPS—

FY2028

Rev+59.45%

EPS—

FY2029

Rev+45.10%

EPS—

Earnings Surprises

Beat rate:33%(4/12 quarters)

Avg surprise:-69.7%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Apr 24, 2025UBS

Coherus Biosciences price target lowered to $1.05 from $1.50 at UBS

Target:$1.05

+0.5%from $1.04

Dec 5, 2024Robert W. Baird

Coherus Biosciences (CHRS) PT Raised to $6 at Baird

Target:$6.00

+245.8%from $1.74

Nov 14, 2022J.P. Morgan

JP Morgan Maintains Neutral on Coherus BioSciences, Lowers Price Target to $11

Target:$11.00

+41.2%from $7.79

Jun 13, 2022UBS

Coherus Biosciences initiated with a Neutral at UBS

Target:$7.00

+13.1%from $6.19

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance